This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Shenzhen Vitavitro Biotech Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations by Xiaozhen Lin in Microfluidic Technology
Introduction
Xiaozhen Lin is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of microfluidics, particularly in the treatment of single cells. His innovative work has led to the development of a unique microfluidic chip and device that enhances the physicochemical treatment of individual cells.
Latest Patents
Xiaozhen Lin holds a patent for a microfluidic chip and microfluidic device designed for physicochemically treating single cells. The patent describes a microfluidic chip that accommodates cells with diameters ranging from 50 to 400 micrometers. The chip features a fluidic layer, a pneumatic layer, and an elastic film, which work together to facilitate the treatment process. The fluidic layer includes various channels for reagent inflow, mixing, and waste management, while the pneumatic layer contains micro-valves for precise control of the treatment process.
Career Highlights
Xiaozhen Lin is currently associated with Shenzhen Vitavitro Biotech Co., Ltd. His work at the company focuses on advancing microfluidic technologies that have applications in biomedical research and diagnostics. His innovative approach has positioned him as a key figure in the field.
Collaborations
Xiaozhen Lin collaborates with notable colleagues, including Jie Wu and Yanjing Fang, who contribute to his research and development efforts. Their teamwork enhances the potential for breakthroughs in microfluidic applications.
Conclusion
Xiaozhen Lin's contributions to microfluidic technology exemplify the innovative spirit of modern science. His patented inventions are paving the way for advancements in single-cell treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile